ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTSDaniela A Bota, Jinah Chung, Manisha Dandekar,Jose A Carrillo,Xiao-tang Kong,Dan Beverly Fu,Frank P K Hsu, Alex H Schönthal,Florence M Hofman,Thomas C Chen,Raphael Zidovetzki,Chrystel Pretto,Ankie Strik,Virgil E J C Schijns,Apostolos StathopoulosNeuro-oncology（2018）引用 2|浏览26暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
